Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.00427 | uM | 12305.156 | 0.7176 | 0.7847 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.0213 | uM | 12305.156 | 0.6039 | 0.6821 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.107 | uM | 12305.156 | 0.4961 | 0.5724 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.533 | uM | 12305.156 | 0.4834 | 0.5584 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 2.67 | uM | 12305.156 | 0.4548 | 0.5261 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 13.3 | uM | 12305.156 | 0.4097 | 0.4725 | 2.9137 | |
| BT-549 | TNBC | Basal B | Everolimus | MTOR | MTOR | 66.7 | uM | 12305.156 | 0.3973 | 0.4569 | 2.9137 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.000171 | uM | 12070.164 | 0.9978 | 0.9964 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.000853 | uM | 12070.164 | 0.9566 | 0.9278 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.00427 | uM | 12070.164 | 0.7449 | 0.5670 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.0213 | uM | 12070.164 | 0.5845 | 0.2817 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.107 | uM | 12070.164 | 0.3553 | -0.1515 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 0.533 | uM | 12070.164 | 0.2998 | -0.2629 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 2.67 | uM | 12070.164 | 0.2777 | -0.3082 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 13.3 | uM | 12070.164 | 0.2598 | -0.3454 | 1.2068 | |
| CAMA-1 | HR+ | Luminal | Everolimus | MTOR | MTOR | 66.7 | uM | 12070.164 | 0.0609 | -0.8032 | 1.2068 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 12112.164 | 0.9425 | 0.9395 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 12112.164 | 0.9526 | 0.9502 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 12112.164 | 0.8656 | 0.8557 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 12112.164 | 0.8351 | 0.8215 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 12112.164 | 0.6343 | 0.5792 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 12112.164 | 0.6456 | 0.5938 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 12112.164 | 0.6815 | 0.6392 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 12112.164 | 0.5848 | 0.5140 | 1.9275 | |
| HCC1143 | TNBC | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 12112.164 | 0.0302 | -0.6745 | 1.9275 |